Matthew Kaplan
Stock Analyst at Ladenburg Thalmann
(2.78)
# 1,683
Out of 5,172 analysts
25
Total ratings
60.87%
Success rate
17.81%
Average return
Main Sectors:
Stocks Rated by Matthew Kaplan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $319 → $344 | $524.28 | -34.39% | 9 | Oct 31, 2024 | |
| URGN UroGen Pharma | Maintains: Buy | $48 → $54 | $17.62 | +203.63% | 1 | Jun 14, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $39 → $40 | $30.07 | +33.02% | 3 | May 2, 2024 | |
| LQDA Liquidia | Maintains: Buy | $15 → $30 | $36.41 | -17.61% | 2 | Dec 21, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $7.5 → $8.5 | $5.31 | +60.08% | 4 | Aug 3, 2023 | |
| KPRX Kiora Pharmaceuticals | Reiterates: Buy | $1,071 | $2.09 | +51,144.02% | 2 | Feb 8, 2023 | |
| XAIR Beyond Air | Maintains: Buy | $340 → $460 | $0.79 | +58,209.04% | 1 | Jun 29, 2022 | |
| LPCN Lipocine | Upgrades: Buy | $51 | $7.15 | +613.29% | 1 | Dec 10, 2020 | |
| COGT Cogent Biosciences | Initiates: Buy | $16 | $33.38 | -52.07% | 1 | Oct 14, 2020 | |
| TARA Protara Therapeutics | Initiates: Buy | $45 | $5.21 | +763.72% | 1 | Jan 22, 2020 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319 → $344
Current: $524.28
Upside: -34.39%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48 → $54
Current: $17.62
Upside: +203.63%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39 → $40
Current: $30.07
Upside: +33.02%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15 → $30
Current: $36.41
Upside: -17.61%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5 → $8.5
Current: $5.31
Upside: +60.08%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.09
Upside: +51,144.02%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340 → $460
Current: $0.79
Upside: +58,209.04%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $7.15
Upside: +613.29%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $33.38
Upside: -52.07%
Protara Therapeutics
Jan 22, 2020
Initiates: Buy
Price Target: $45
Current: $5.21
Upside: +763.72%